Literature DB >> 30342090

An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models.

Ela Markovsky1, Sadna Budhu2, Robert M Samstein1, Hongyan Li1, James Russell3, Zhigang Zhang4, Esther Drill4, Chloe Bodden1, Qing Chen3, Simon N Powell1, Taha Merghoub2, Jedd D Wolchok2, John Humm3, Joseph O Deasy3, Adriana Haimovitz-Friedman5.   

Abstract

PURPOSE: This study examined tumor growth delay resulting from partial irradiation in preclinical mouse models. METHODS AND MATERIALS: We investigated 67NR murine orthotopic breast tumors in both immunocompetent and nude mice. Treatment was delivered to 50% or 100% of the tumor using a 2 × 2 cm collimator on a microirradiator. Radiation response was modulated by treatment with anti-CD8 and anti-intercellular adhesion molecule (anti-ICAM) antibodies. Similar experiments were performed using the less immunogenic Lewis lung carcinoma mouse model. Tumor growth delay and γ-H2AX phosphorylation were measured, and immune response was assessed by immunofluorescence and flow cytometry at 1 and 7 days after radiation therapy. Tumor expression of cellular adhesion molecules was also measured at different times after radiation therapy.
RESULTS: Partial irradiation led to tumor responses similar to those of fully exposed tumors in immunocompetent mice, but not in nude mice. After a single dose of 10 Gy, infiltration of CD8+ T cells was observed along with increased expression of ICAM. The response to 10 Gy in hemi-irradiated tumors was abrogated by treatment with either anti-CD8 or anti-ICAM antibodies. Similar responses were obtained in the less immunogenic Lewis lung carcinoma mouse model delivering 15 Gy to half the tumor volume. Treatment with FTY720, a compound that inhibits T-cell egress from lymph nodes, did not affect tumor response at the time of CD8+ T cells infiltration in the nonirradiated area of the tumor. This result indicated that the most likely source of these cells is the irradiated portion of the hemi-irradiated tumors. In addition, a significant abscopal effect was observed after partial irradiation with a single dose of 10 Gy in the 67NR model.
CONCLUSIONS: In these models, radiation controls tumor growth both directly through cell killing and indirectly through immune activation. This outcome raises the possibility that this effect could be induced in the clinic.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30342090      PMCID: PMC6764416          DOI: 10.1016/j.ijrobp.2018.10.009

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  46 in total

Review 1.  Stress signaling from irradiated to non-irradiated cells.

Authors:  E I Azzam; S M de Toledo; J B Little
Journal:  Curr Cancer Drug Targets       Date:  2004-02       Impact factor: 3.428

2.  ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow.

Authors:  Lin Yang; Richard M Froio; Tracey E Sciuto; Ann M Dvorak; Ronen Alon; Francis W Luscinskas
Journal:  Blood       Date:  2005-04-05       Impact factor: 22.113

3.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.

Authors:  Stephan Gasser; Sandra Orsulic; Eric J Brown; David H Raulet
Journal:  Nature       Date:  2005-07-03       Impact factor: 49.962

Review 4.  Radiation-induced normal tissue injury: role of adhesion molecules in leukocyte-endothelial cell interactions.

Authors:  S Quarmby; P Kumar; S Kumar
Journal:  Int J Cancer       Date:  1999-07-30       Impact factor: 7.396

5.  Engaging the vascular component of the tumor response.

Authors:  Zvi Fuks; Richard Kolesnick
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

Review 6.  The controversial abscopal effect.

Authors:  Joseph M Kaminski; Eric Shinohara; James Bradley Summers; Kenneth J Niermann; Allan Morimoto; Jeffrey Brousal
Journal:  Cancer Treat Rev       Date:  2005-05       Impact factor: 12.111

7.  Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.

Authors:  D H Gorski; M A Beckett; N T Jaskowiak; D P Calvin; H J Mauceri; R M Salloum; S Seetharam; A Koons; D M Hari; D W Kufe; R R Weichselbaum
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

8.  External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.

Authors:  Mala Chakraborty; Scott I Abrams; C Norman Coleman; Kevin Camphausen; Jeffrey Schlom; James W Hodge
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

9.  Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Authors:  Monica Garcia-Barros; Francois Paris; Carlos Cordon-Cardo; David Lyden; Shahin Rafii; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

10.  Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated.

Authors:  Sandra Demaria; Bruce Ng; Mary Louise Devitt; James S Babb; Noriko Kawashima; Leonard Liebes; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

View more
  16 in total

1.  ICAM-1 orchestrates the abscopal effect of tumor radiotherapy.

Authors:  Yang Zhao; Ting Zhang; Yanpu Wang; Dehua Lu; Jinhong Du; Xun Feng; Haoyi Zhou; Ning Liu; Hua Zhu; Shangbin Qin; Chenxin Liu; Xianshu Gao; Zhi Yang; Zhaofei Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

2.  Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations.

Authors:  Andrew J Johnsrud; Samir V Jenkins; A Jamshidi-Parsian; Charles M Quick; Edvaldo P Galhardo; Ruud P M Dings; Kieng B Vang; Ganesh Narayanasamy; Issam Makhoul; Robert J Griffin
Journal:  Radiat Res       Date:  2020-12-01       Impact factor: 2.841

Review 3.  A Current Review of Spatial Fractionation: Back to the Future?

Authors:  Cole Billena; Atif J Khan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-01-23       Impact factor: 7.038

Review 4.  Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists.

Authors:  Alice Y Ho; Jean L Wright; Rachel C Blitzblau; Robert W Mutter; Dan G Duda; Larry Norton; Aditya Bardia; Laura Spring; Steven J Isakoff; Jonathan H Chen; Clemens Grassberger; Jennifer R Bellon; Sushil Beriwal; Atif J Khan; Corey Speers; Samantha A Dunn; Alastair Thompson; Cesar A Santa-Maria; Ian E Krop; Elizabeth Mittendorf; Tari A King; Gaorav P Gupta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-05-14       Impact factor: 7.038

Review 5.  Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?

Authors:  Jonathan Khalifa; Julien Mazieres; Carlos Gomez-Roca; Maha Ayyoub; Elizabeth Cohen-Jonathan Moyal
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

6.  An investigation of kV mini-GRID spatially fractionated radiation therapy: dosimetry and preclinical trial.

Authors:  Timothy R Johnson; Alex M Bassil; Nerissa T Williams; Simon Brundage; Collin L Kent; Greg Palmer; Yvonne M Mowery; Mark Oldham
Journal:  Phys Med Biol       Date:  2022-02-18       Impact factor: 4.174

Review 7.  Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review.

Authors:  Wu-Yan Xia; Wen Feng; Chen-Chen Zhang; Yu-Jia Shen; Qin Zhang; Wen Yu; Xu-Wei Cai; Xiao-Long Fu
Journal:  Transl Lung Cancer Res       Date:  2020-10

Review 8.  Immunostimulatory Effects of Radiotherapy for Local and Systemic Control of Melanoma: A Review.

Authors:  Junko Takahashi; Shinsuke Nagasawa
Journal:  Int J Mol Sci       Date:  2020-12-07       Impact factor: 5.923

9.  Spatially fractionated radiotherapy (SFRT) targeting the hypoxic tumor segment for the intentional induction of non-targeted effects: An in silico study to exploit a new treatment paradigm.

Authors:  M Massaccesi; L Boldrini; A Piras; G Stimato; F Quaranta; L Azario; G C Mattiucci; V Valentini
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2020-03-02

10.  Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.

Authors:  Jason J Luke; Benjamin E Onderdonk; Sean P Pitroda; Steven J Chmura; Sandeep R Bhave; Theodore Karrison; Jeffrey M Lemons; Paul Chang; Yuanyuan Zha; Tim Carll; Thomas Krausz; Lei Huang; Carlos Martinez; Linda A Janisch; Robyn D Hseu; John W Moroney; Jyoti D Patel; Nikolai N Khodarev; Joseph K Salama; Patrick A Ott; Gini F Fleming; Thomas F Gajewski; Ralph R Weichselbaum
Journal:  Clin Cancer Res       Date:  2020-10-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.